AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study. In the Phase 3 ...

AbbVie plans to present the full results at medical conferences and expects additional trial data from TEMPO-2 by the end of 2024. Tavapadon is an investigational D1/D5 dopamine receptor partial ...

The U.S. Food and Drug Administration has scolded AbbVie for making false and misleading claims in a TV ad about a migraine pill that features Serena Williams, the third time this year the agency ...

The endorsement follows the recent announcement that AbbVie (NYSE:ABBV) and Ripple Therapeutics have entered into a partnership to develop a new drug delivery implant, RTC-620. This product is ...

Sept 9 (Reuters) - Pharmaceutical giant AbbVie (ABBV.N), opens new tab has sued cancer treatment maker BeiGene (6160.HK), opens new tab in Chicago federal court, accusing it of stealing trade ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

The endorsement follows the recent announcement that AbbVie (NYSE:ABBV) and Ripple Therapeutics have entered into a partnership to develop a new drug delivery implant, RTC-620. This product is ...

Vandana Singh TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as ...

In a lawsuit filed Friday, lawyers for AbbVie argued that BeiGene “enticed and encouraged” former AbbVie scientist Huaqing Liu, who’s named as a defendant in the case, to jump ship and share ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...